Market Estimates
Valuation Metrics
Financials
Trading Trends
APLS News & Events
Events Timeline

No data
News
People Also Watch
Frequently Asked Questions
What is Apellis Pharmaceuticals Inc (APLS) stock price today?
The current price of APLS is 27.3 USD — it has increased 3.96 % in the last trading day.
What is Apellis Pharmaceuticals Inc (APLS)'s business?
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
What is the price predicton of APLS Stock?
Wall Street analysts forecast APLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLS is 33.07 USD with a low forecast of 18.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
What is Apellis Pharmaceuticals Inc (APLS)'s revenue for the last quarter?
Apellis Pharmaceuticals Inc revenue for the last quarter amounts to 458.58M USD, increased 132.98 % YoY.
What is Apellis Pharmaceuticals Inc (APLS)'s earnings per share (EPS) for the last quarter?
Apellis Pharmaceuticals Inc. EPS for the last quarter amounts to 1.66 USD, decreased -460.87 % YoY.
What changes have occurred in the market's expectations for Apellis Pharmaceuticals Inc (APLS)'s fundamentals?
How many employees does Apellis Pharmaceuticals Inc (APLS). have?
Apellis Pharmaceuticals Inc (APLS) has 705 emplpoyees as of January 10 2026.
What is Apellis Pharmaceuticals Inc (APLS) market cap?
Today APLS has the market capitalization of 3.45B USD.



![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F20260110050344_fd631ca9cc459953cfe9cd75ca0ad768.jpg&w=384&q=75)
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F20260108030305_7766e544dd615cf70be90b951320f016.jpeg&w=384&q=75)
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2Fc60e8a1c3e5d6fba806e519fdee72867a14e482ded4cbb984b50d552a7b06a3f.jpg&w=384&q=75)